A phase I/II trial to evaluate the combination of infliximab and sorafenib in the treatment of renal cell carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Infliximab (Primary) ; Sorafenib
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Aug 2017 Status changed from active, no longer recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 19 Mar 2007 New trial record.